
1. hiv clin trials. 2014 mar-apr;15(2):51-6. doi: 10.1310/hct1502-51.

switching twice-daily raltegravir plus tenofovir disoproxil
fumarate/emtricitabine once-daily
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in
virologically suppressed, hiv-1-infected subjects: 48 weeks data.

mills a(1), crofoot g(2), ortiz r(3), rashbaum b(4), towner w(5), ward d(6),
brinson c(7), kulkarni r(8), garner w(8), ebrahimi r(8), cao h(8), cheng a(8),
szwarcberg j(8).

author information: 
(1)anthony mills md, los angeles, california.
(2)g. crofoot, houston, texas.
(3)orlando immunology center, orlando, florida.
(4)capital med associates, washington, dc.
(5)kaiser permanente, los angeles, california.
(6)dupont circle physician's group, washington, dc.
(7)central texas clinical research, austin, texas.
(8)gilead sciences, inc., foster city, california.

background: pill burden, dosing frequency, concerns safety and
tolerability important obstacles maintaining adequate medication
adherence. raltegravir (ral) indicated twice-daily dosing taken
with emtricitabine (ftc)/tenofovir disoproxil fumarate (tdf), becomes a
twice-daily multiple-tablet regimen. elvitegravir (evg)/cobicistat
(cobi)/ftc/tdf, stb, first approved once-a-day integrase strand transfer
inhibitor (insti) containing single-tablet regimen combines evg, insti,
and cobi, novel pharmacoenhancer, preferred nucleos(t)ide backbone 
ftc/tdf.
methods: 48-week prospective, single-arm open-label study the
switch stb virologically sup-pressed hiv-1-infected adult patients on
ftc/tdf twice-daily ral least 6 months. objectives evaluate
the tolerability safety regimen simplification once-a-day stb, 
maintaining viral suppression 48 weeks.
results: forty-eight individuals united states enrolled. median
age 44 years, 96% male, 83% white. median time ral +
ftc/tdf treatment prior enrollment 34 months. ninety-six percent of
participants cited regimen simplification reason enroll switch
study. base-line, median cd4 count 714 cell/Âµl estimated
glomerular filtration rate (egfr) 105 ml/min. week 48, assessed study 
participants remained viro-logically suppressed lower limit of
quantification (hiv-1 rna<50 copies/ml) maintained high cd4 cell count
(median, 751 cells/ml) stable egfr (median, 100.5 ml/min). stb well
tolerated discontinuations, study drug-related serious adverse events,
and study drug-related grade 3/4 adverse events.
conclusions: participants switching 1 tablet once-a-day stb a
twice-daily ral + ftc/tdf regimen remained virologically suppressed. stb well
tolerated. switching stb may viable option virologically suppressed
patients wanting simplify twice-daily ral-containing regimen.

doi: 10.1310/hct1502-51 
pmid: 24710918  [indexed medline]

